ALK and non-small cell lung carcinoma: A subsequent trial that randomized chemotherapy-naïve patients with advanced ALK-positive NSCLC to receive crizotinib or chemotherapy showed longer progression free survival in the crizotinib arm compared to chemotherapy, although no difference in overall survival was observed (27).